NCT02314403View on ClinicalTrials.gov

Renal Allograft Tolerance Through Mixed Chimerism (Belatacept)

PHASE1CompletedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

February 28, 2015

Primary Completion Date

March 31, 2021

Study Completion Date

July 31, 2021

Conditions
Kidney Failure, ChronicRenal Insufficiency
Interventions
DRUG

Belatacept

A selective T-cell (lymphocyte) costimulation blocker

DRUG

ATG

A T-Cell Depleting Agent

DRUG

Rituximab

B-Cell Depleting Agent

RADIATION

Total Body Irradiation

RADIATION

Thymic Irradiation

PROCEDURE

Combined Bone Marrow/Kidney Transplantation

Trial Locations (1)

02114

Massachusetts General Hospital, Boston

All Listed Sponsors
lead

Massachusetts General Hospital

OTHER

NCT02314403 - Renal Allograft Tolerance Through Mixed Chimerism (Belatacept) | Biotech Hunter | Biotech Hunter